Skip to main content
Equibles
LNAI logo

LNAI · Lunai Bioworks Inc. · Documents

Track LNAI — free

Use LNAI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LNAI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.16 -0.07 (-30.17%) At close · Oct 29
Rebalance outlook locked
Going-concern doubt — flagged Oct 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the financial statements are issued. ... management has concluded that substantial doubt about the Company's ability to continue as a going concern has not been alleviated.”
View the 10-K filed Oct 13, 2026
Market Cap
$829,677
Shares
5.03M
Volume · Oct 29 1.28M Avg daily vol (3M) 394.64K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2026 Revenue $51.99K 10-K filed Oct 13, 2026 Quarterly report FY2026 Q3 Revenue $20.94K 10-Q filed May 15, 2026
2026
Oct 13
Annual report 10-K FY2026, ended Jun 30
Annual report for FY2026

Lunai Bioworks Inc. completed the Neurobridge IP Holdings Incorporated acquisition on May 1, 2026 for Series B preferred stock with an aggregate stated value of $20.0 million. It reported a net loss of $3,562,479 for fiscal 2026 and less than one month of available cash as of October 13, 2026.

Revenue $51.99K Net loss $3.56M Diluted EPS -$1.06
Read from the MD&A section
Oct 9
Current report 8-K
Other events

On October 9, 2026, Lunai Bioworks, Inc. asked Nasdaq to immediately suspend trading in its common stock, citing records from pending litigation; Nasdaq had not decided, and the request did not halt trading.

Sep 29
Late filing notice NT 10-K
Late filing notice

Lunai Bioworks Inc. anticipates a net loss of approximately $3.2 million for fiscal 2026, versus approximately $178.0 million for fiscal 2025, and plans to file its annual report by the fifteenth calendar day after the prescribed due date.

Jun 17
Current report 8-K
Other events AI summary on its way
Jun 16
Current report 8-K Events of Jun 11
Other events AI summary on its way
May 20
Current report 8-K
Other events AI summary on its way
May 15
Quarterly report 10-Q FY2026 Q3, ended Mar 31
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $20.94K Net loss $2.57M Diluted EPS -$0.10
Apr 28
Current report 8-K Events of Apr 27
Other events AI summary on its way
Mar 5
Current report 8-K Events of Feb 27
Other events AI summary on its way
2025
Showing 1–50 of 205 documents
Key facts CIK 1527728 CUSIP 29350E302 13F (30d) 2 filings 2 filers Visit website Investor relations